Hereditary hemorrhagic telangiectasia (HHT/Osler-Weber-Rendu)
Log in to starLast updated Nov 3, 2026
A patient with recurrent epistaxis has mucocutaneous telangiectasias on lips and fingers. CT reveals pulmonary AVMs.
AD; ENG (endoglin, HHT1), ACVRL1 (activin receptor type-1-like, also called ALK1, HHT2), SMAD4 (JP-HHT); loss-of-function (null) variants in TGF-beta pathway genes
All known HHT genes encode proteins of the transforming growth factor beta (TGF-beta) signaling pathway. Endoglin is part of the TGF-beta receptor complex, and activin receptor type-1-like is a type I receptor for TGF-beta superfamily ligands; both are expressed mainly on endothelial cells. SMAD4 protein carries the signal inside the cell in the TGF-beta/BMP pathway. The mechanism is loss of function: essentially all known pathogenic variants are null alleles, and no specific variant or variant type predicts the phenotype.
- ENG (HHT1, 44%): pulmonary and cerebral AVMs are more common.
- ACVRL1 (HHT2, 52%): hepatic AVMs are more common, as is pulmonary hypertension without severe shunting.
- SMAD4 (JP-HHT, 1%): juvenile polyposis with HHT. About 95% show features of HHT, and thoracic aortopathy is reported in 31%-38%.
Both ENG and ACVRL1 disease affect many vascular beds, so the gene cannot be predicted from the clinical picture. Any SMAD4 pathogenic variant is taken to carry the risks of both juvenile polyposis and HHT.
- Mucocutaneous telangiectasias (lips, tongue, fingers)
- Recurrent epistaxis
- Visceral AVMs: pulmonary, hepatic, cerebral, GI
- SMAD4: overlap with juvenile polyposis
Complications:
- Pulmonary AVMs → stroke, brain abscess (paradoxical emboli)
- GI bleeding
- High-output heart failure (hepatic AVMs)
- Clinical diagnosis by Curaçao criteria (definite if ≥3 of 4): recurrent spontaneous epistaxis, mucocutaneous telangiectasias, visceral AVMs (pulmonary, hepatic, cerebral, GI), and a first-degree relative with HHT
- Genetic testing (ENG, ACVRL1, SMAD4) confirms the diagnosis and enables cascade screening of at-risk relatives
- Screening for occult AVMs: contrast echocardiography (bubble study) for pulmonary AVMs, MRI for cerebral AVMs; consider SMAD4 testing for combined juvenile polyposis-HHT (adds GI/colon surveillance)
- Embolization of pulmonary AVMs to prevent paradoxical embolic stroke and brain abscess; antibiotic prophylaxis for dental/surgical procedures in patients with pulmonary AVMs
- Epistaxis: humidification and topical measures first-line; antifibrinolytics (tranexamic acid) and bevacizumab for refractory bleeding
- Iron supplementation/transfusion for chronic blood-loss anemia
- Cerebral AVMs managed individually (embolization, surgery, or radiosurgery) by a multidisciplinary team
Genes from diagnostic criteria: Make groups of 3 letters from the gene names ACVRL1 and ENG:
- ACV = Arteries Connect to Veins (AVMs)
- RL1 = you have an affected ReLative (1st degree relative, a diagnostic criterion)
- ENG = Epistaxis & NoGgin bleeds

Sturge-Weber vs HHT: Sturge-Weber has 1 gene (GNAQ), 1 place on body, and 1 dash in the name. HHT (Osler-Weber-Rendu) has 2 dashes, multiple genes, and multiple places on the body